Statement: Febrile neutropenia was in excess of 5 times more common in cohort 1 of the primary trial, than in cohort 2.
Primary_evidence: Adverse Events 1:   Total: 122/280 (43.57%)   Agranulocytosis 0/280 (0.00%)   Anaemia 10/280 (3.57%)   Febrile neutropenia 30/280 (10.71%)   Immune thrombocytopenic purpura 1/280 (0.36%)   Leukopenia 3/280 (1.07%)   Neutropenia 12/280 (4.29%)   Thrombocytopenia 4/280 (1.43%)   Acute myocardial infarction 1/280 (0.36%)   Cardiac failure 1/280 (0.36%)   Cataract 2/280 (0.71%) Adverse Events 2:   Total: 58/282 (20.57%)   Agranulocytosis 1/282 (0.35%)   Anaemia 2/282 (0.71%)   Febrile neutropenia 4/282 (1.42%)   Immune thrombocytopenic purpura 0/282 (0.00%)   Leukopenia 0/282 (0.00%)   Neutropenia 3/282 (1.06%)   Thrombocytopenia 1/282 (0.35%)   Acute myocardial infarction 0/282 (0.00%)   Cardiac failure 0/282 (0.00%)   Cataract 1/282 (0.35%)   Cataract subcapsular 1/282 (0.35%)